Sabarish Ram Ayyappan, MD, discusses findings from the final analysis of the phase 2 ELM-2 trial of odronextamab in a cohort of patients with relapsed/refractory diffuse large B-cell lymphoma.
Sabarish Ram Ayyappan, MD
Advertisement
Sabarish Ram Ayyappan, MD, is the medical director of hematologic malignancies at City of Hope in Atlanta, GA.
Articles by Sabarish Ram Ayyappan, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Insurance Delays and Travel Strain CAR T Referral in Early Relapsed Myeloma
2
NCCN Guidelines Add Cosibelimab for Locally Advanced CSCC
3
Oncologists Debate Role of On-Body Injector for Transplant-Ineligible Myeloma
4
Rusfertide Improves Hematocrit Control, Reduces Phlebotomy in Polycythemia Vera
5